Wednesday, 13 Nov 2019

You are here

Less Structural Damage with T2T in Gout

A two‐year randomized clinical trial has demonstrated that allopurinol dose escalation to a target serum urate (SU) results in less bone erosion, structural damage and urate crystal deposition in patients with gout.

A prospective, two‐year clinical trial randomized 87 gout patients to received either convential allopurinol dosing or treat-to-target (T2T) dose escalation to achieve a target serum urate < 6mg/dl. Subjects underwent dual energy CT (DECT) scans of the feet, and radiographs (XR, hand and foot) at yearly intervals and DECT scans were scored for bone erosion and urate volume.

After 2 years, CT erosion score was higher in the control group compared in the T2T (+7.8% change vs +1.4% in the T2T group, Prandomization =0.015).

While changes in XRay erosion or narrowing scores did not differ between groups, DECT scans showed that urate volumes in the dose escalation group had reduced DECT urate volume (‐27.6 to ‐28.3%) at year 2 (p=0.023).

These findings provide evidence that imaging evidence that long‐term urate‐lowering therapy, adjusted to achieve a target serum urate can influence structural outcomes in gout.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

T2T Lowers Mortality in Gout

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

Novel Inhibition of MSU Crystal Inflammation

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Monosodium urate (MSU) crystals directly activate the inflammasome to produce a plethora of pro-inflammatory cytokines, including interleukin-1β (IL-1β). 

Patients Prefer Nurse Led Care for their Gout

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level < 6 mg/dl, this goal is seldom achieved (< 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.

Anakinra Use in Hospitalized Gout Patients

While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.

Higher Rates of Venous Thromboembolism in Gout

A Canadian administrative claims analysis has shown that gout-associated inflammation increases the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) before and after the diagnosis of gout.